AN2 Therapeutics Announces Epetraborole Granted Orphan Drug Designation in the U.S. for the Treatment of Infections Caused by Non-Tuberculous Mycobacteria

MENLO PARK, Calif.: MENLO PARK, Calif., Feb. 16, 2022 /PRNewswire/ -- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to epetraborole...

Click to view original post